Distinction between mog antibodypositive and aqp4 antibody-positive nmo spectrum disorders

Neurology

Volumn 83, Issue 12, 2014, Pages 1122-1123

  Mao, Zhifeng ^a   Lu, Zhengqi ^a   Hu, Xueqiang ^a   Sato, Douglas Kazutoshi ^a   Callegaro, Dagoberto ^a   Lana Peixoto, Marco Aurelio ^a   Nakashima, Ichiro ^a   Fujihara, Kazuo ^a  

^a NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AQUAPORIN 4 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; AQUAPORIN 4; AUTOANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTICENTER STUDY (TOPIC); MYELOOPTIC NEUROPATHY; NOTE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; VISUAL ACUITY; VISUAL IMPAIRMENT; WALKING DIFFICULTY; FEMALE; IMMUNOLOGY; MALE;

AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA;

EID: 84920269264     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000830     Document Type: Note

References (7)

1. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibodypositive NMO spectrum disorders. Neurology 2014;82: 474-481.
2. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-283.
3. Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004;61:1401-1405.
4. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011;8:184.
5. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-461.
6. Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 2014;270:98-99.
7. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. Neurology 2013;81:76-83.